<DOC>
	<DOCNO>NCT00420420</DOCNO>
	<brief_summary>The purpose study test efficacy safety investigational medication improve symptom Alzheimer 's Disease . Subjects receive either active medication placebo 28 day . Tests memory , concentration include . Safety monitor use routine clinical laboratory test .</brief_summary>
	<brief_title>MK0249 Symptomatic Treatment Alzheimer 's Disease ( MK0249-011 )</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Male female Age least 55 year old Mildtomoderate Alzheimer 's Disease , Mini Mental State Examination ( MMSE ) 18 26 , inclusive , Modified Hachinski Ischemic Scale ( MHIS ) score =/ &lt; 4 , Global CDR score 1 2 , reliable informant/caregiver accompany patient clinic visit If use symptomatic Alzheimer 's Disease treatment , patient must medication 3 month STABLE DOSE least 2 month Patients live skilled nursing facility Patients poorlycontrolled hypertension Patients follow condition within 6 month screen : significant cardiovascular disorder , active major depressive disorder , gastroesophageal reflux disease ( GERD ) , clinically significant sleep disorder Various concomitant therapy restriction</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>